All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?
Featured:
Nitin JainDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nitin Jain, MD Anderson Cancer Center, Houston, US. We asked, Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?
BALLI-01 Study: Is UCART22, an allogeneic anti-CD22 CAR T-cell product, safe and effective?
Jain provides an update on a trial evaluating UCART22 in adult patients with relapsed/refractory B-cell ALL. Jain starts by discussing the advantages of using allogeneic T-cell products. He then discusses the safety and efficacy results of the trial and finishes by outlining future adjustments of protocols to promote the persistence of UCART22.